The main aim of this thesis was the evaluation of advances in the management of JIA. It focused on developments in the biologic treatment of JIA, using data from the ABC register. Additionally, it explored new biomarkers and methods for monitoring the disease activity, bone age and bone health of patients with JIA.

Additional Metadata
Keywords Juvenile idiopathic arthritis (JIA), biological treatment
Promotor A.J. van der Heijden (Bert)
Publisher Erasmus University Rotterdam
Sponsor The ABC register was financially supported by the Dutch Board of Health Insurances (from 2003 to 2006), Pfizer (formerly Whyeth International, from 2007 to 2013) and AbbVie (formerly Abbott (from 2010 to 2012)). Printing of this thesis was financially supported by the Erasmus University Rotterdam, Dutch Arthritis Foundation (Reumafonds), Pfizer B.V., AbbVie B.V. and UCB Pharma B.V.
ISBN 978-90-90-28781-2
Persistent URL hdl.handle.net/1765/77543
Anink, J. (2015, February 11). Advances in the Management of Juvenile Idiopathic Arthritis. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/77543